Literature DB >> 33375130

Metabolic Reprogramming by Malat1 Depletion in Prostate Cancer.

Simona Nanni1, Aurora Aiello2, Chiara Salis3, Agnese Re2, Chiara Cencioni2, Lorenza Bacci3, Francesco Pierconti1, Francesco Pinto1, Cristian Ripoli1, Paola Ostano4, Silvia Baroni1, Giacomo Lazzarino5, Barbara Tavazzi1, Dario Pugliese3, PierFrancesco Bassi1, Claudio Grassi1, Simona Panunzi2, Giovanna Chiorino4, Alfredo Pontecorvi1, Carlo Gaetano6, Antonella Farsetti2.   

Abstract

The lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes growth and progression in prostate cancer (PCa); however, little is known about its possible impact in PCa metabolism. The aim of this work has been the assessment of the metabolic reprogramming associated with MALAT1 silencing in human PCa cells and in an ex vivo model of organotypic slice cultures (OSCs). Cultured cells and OSCs derived from primary tumors were transfected with MALAT1 specific gapmers. Cell growth and survival, gene profiling, and evaluation of targeted metabolites and metabolic enzymes were assessed. Computational analysis was made considering expression changes occurring in metabolic markers following MALAT1 targeting in cultured OSCs. MALAT1 silencing reduced expression of some metabolic enzymes, including malic enzyme 3, pyruvate dehydrogenase kinases 1 and 3, and choline kinase A. Consequently, PCa metabolism switched toward a glycolytic phenotype characterized by increased lactate production paralleled by growth arrest and cell death. Conversely, the function of mitochondrial succinate dehydrogenase and the expression of oxidative phosphorylation enzymes were markedly reduced. A similar effect was observed in OSCs. Based on this, a predictive algorithm was developed aimed to predict tumor recurrence in a subset of patients. MALAT1 targeting by gapmer delivery restored normal metabolic energy pathway in PCa cells and OSCs.

Entities:  

Keywords:  MALAT1; biomarkers; long non-coding RNA; metabolic reprogramming; metabolism; precision medicine; predictive model; prostate cancer; transcription

Year:  2020        PMID: 33375130     DOI: 10.3390/cancers13010015

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  MALAT1 as a Regulator of the Androgen-Dependent Choline Kinase A Gene in the Metabolic Rewiring of Prostate Cancer.

Authors:  Sara De Martino; Egidio Iorio; Chiara Cencioni; Aurora Aiello; Francesco Spallotta; Mattea Chirico; Maria Elena Pisanu; Claudio Grassi; Alfredo Pontecorvi; Carlo Gaetano; Simona Nanni; Antonella Farsetti
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

2.  Long Noncoding RNA MALAT1 Promotes Laryngocarcinoma Development by Targeting miR-708-5p/BRD4 Axis to Regulate YAP1-Mediated Epithelial-Mesenchymal Transition.

Authors:  Xiaoqin Wu; Yenong Tan; Xuxia Tang
Journal:  Biomed Res Int       Date:  2022-05-12       Impact factor: 3.246

3.  LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma.

Authors:  Zhencong Chen; Zhengyang Hu; Qihai Sui; Yiwei Huang; Mengnan Zhao; Ming Li; Jiaqi Liang; Tao Lu; Cheng Zhan; Zongwu Lin; Fenghao Sun; Qun Wang; Lijie Tan
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

4.  MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.

Authors:  Maximilian Marhold; Simon Udovica; Thais Topakian; Peter Horak; Reinhard Horvat; Erwin Tomasich; Gerwin Heller; Michael Krainer
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

Review 5.  Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases.

Authors:  Juan Carlos Lacal; Tahl Zimmerman; Joaquín M Campos
Journal:  Pharmaceutics       Date:  2021-05-25       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.